Durvalumab in Combination with BCG for BCG-Naïve High-Risk NMIBC: Final Analysis of the Phase 3, Open-Label, Randomized POTOMAC Trial - report from ESMO 2025

13/11/2025 3 min

Listen "Durvalumab in Combination with BCG for BCG-Naïve High-Risk NMIBC: Final Analysis of the Phase 3, Open-Label, Randomized POTOMAC Trial - report from ESMO 2025"

Episode Synopsis

Professor Maria De Santis shares her thoughts on the final analysis of the phase 3, open-Label, randomized POTOMAC trial were presented at the ESMO Congress 2025.Video: https://medicaldigest.org/scientific-contents/interview:durvalumab-combination-bcg-bcg-naive-high-risk-nmibc-final-analysis-phase-3-open-label-randomized-potomac-trial

More episodes of the podcast Medical Digest & Congress Report